Adimab has expanded its roster of high-profile partners for its yeast-based human antibody discovery and optimisation platform. Biogen Idec and Novo Nordisk have each signed up to research collaborations in which Adimab will identify fully human antibodies against two targets selected by the partner company. The agreements provide both companies with the option to commercialise antibodies generated from the collaboration.